The use of danazol in the management of chronic immune thrombocytopenic purpura


Dr B. A. McVerry, Department of Haematology, Royal Liverpool Hospital, Prescot Street, Liverpool L69 3BX.


Summary. Danazol has recently been reported to be an effective mode of treatment for patients with refractory immune thrombocytopenic purpura. Following a 3 month trial of danazol, only one of 10 patients experienced a sustained increase in platelet counts and two other patients had a transient improvement. While the drug was well tolerated, it does not appear to be particularly helpful in the management of these patients.